• Cisplatin in Cancer Research: Mechanisms, Chemoresistance...

  2026-04-02

  Explore the multifaceted role of Cisplatin as a DNA crosslinking agent for cancer research, with a special focus on apoptosis, chemoresistance, and patient-derived xenograft models. Uncover advanced scientific insights and practical guidance on leveraging Cisplatin’s mechanisms for translational oncology.

• (S)-(+)-Ibuprofen: Selective COX Inhibitor for Inflammati...

  2026-04-02

  (S)-(+)-Ibuprofen is a pharmacologically active ibuprofen enantiomer and a benchmark COX inhibitor widely used in inflammation pathway and pain mechanism studies. Its selective inhibition of COX-1 and COX-2, along with high solubility in DMSO and ethanol, make it ideal for in vitro and in vivo research. Compared to its R-enantiomer, (S)-(+)-Ibuprofen exhibits stronger activity and fewer side effects.

• Angiotensin III (human, mouse): Advanced Mechanistic Insi...

  2026-04-01

  Discover the multifaceted role of Angiotensin III, a key renin-angiotensin-aldosterone system peptide, as both an aldosterone secretion inducer and a pressor activity mediator. This article provides in-depth analysis of its unique receptor interactions, translational applications, and emerging implications for cardiovascular, neuroendocrine, and viral pathogenesis research.

• (S)-(+)-Ibuprofen: Chemical Structure, COX Inhibition, an...

  2026-04-01

  (S)-(+)-Ibuprofen is the pharmacologically active ibuprofen enantiomer, renowned for selective COX inhibition and translational research value. This article uniquely explores its chemical makeup, cutting-edge assay applications, and future directions for inflammation and pain management science.

• Cisplatin in Cancer Research: From Molecular Mechanisms t...

  2026-03-31

  Explore the multifaceted role of Cisplatin as a DNA crosslinking agent for cancer research, with a special focus on apoptosis, chemoresistance, and the interplay with immune checkpoint regulation. Discover how cutting-edge insights into ER stress and PD-L1 stabilization open new avenues for therapeutic innovation.

• Diclofenac: Advanced Approaches for Inflammation and Phar...

  2026-03-31

  Explore how Diclofenac, a non-selective COX inhibitor, is redefining inflammation and pain signaling pathway research with new in vitro and pharmacokinetic models. This article delivers deep scientific insights and practical guidance for leveraging Diclofenac in innovative research applications.

• Ibuprofen (A8446): Cyclooxygenase Inhibitor for Cancer & ...

  2026-03-30

  Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID) and dual cyclooxygenase inhibitor, is a benchmark agent for anti-proliferative and anti-inflammatory studies. APExBIO’s Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) demonstrates reproducible activity in cancer, atherosclerosis, and pain models, with well-defined mechanisms and solubility parameters.

• Cisplatin in Translational Oncology: Mechanistic Rigor, S...

  2026-03-30

  This thought-leadership article provides a comprehensive, mechanistic, and strategic roadmap for translational researchers employing Cisplatin—a gold-standard DNA crosslinking agent—in cancer research. Integrating molecular insights, translational challenges, and actionable guidance, the article explores how APExBIO’s Cisplatin (SKU A8321) empowers rigorous apoptosis assays, chemoresistance studies, and next-generation xenograft models. Drawing on recent evidence—including the pivotal role of Smurf1 in modulating chemosensitivity—the discussion advances beyond conventional product pages to inspire innovation and reproducibility in preclinical and translational oncology.

• Ibuprofen as an Anti-Proliferative Agent in Colon Cancer ...

  2026-03-29

  APExBIO’s Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) empowers researchers with a robust, reproducible cyclooxygenase inhibitor for advanced cancer, inflammation, and atherosclerosis models. This guide delivers hands-on protocols, troubleshooting insights, and comparative analysis to maximize Ibuprofen’s impact as an anti-proliferative agent in translational research.

• Ibuprofen (SKU A8446): Scenario-Driven Solutions for Cell...

  2026-03-28

  This article provides an evidence-based, scenario-driven guide for biomedical researchers and lab technicians using Ibuprofen (SKU A8446) in cell viability, proliferation, and cytotoxicity assays. Drawing on real laboratory challenges, we demonstrate how APExBIO's Ibuprofen addresses solubility, workflow reproducibility, and data interpretation hurdles, with actionable insights and validated protocol recommendations.

• Cisplatin (A8321): DNA Crosslinking Agent for Cancer Rese...

  2026-03-27

  Cisplatin, also known as CDDP, is a gold-standard chemotherapeutic compound and DNA crosslinking agent for cancer research. It induces robust, caspase-dependent apoptosis and is central to studies exploring chemotherapy resistance mechanisms. APExBIO's Cisplatin (SKU A8321) delivers validated, reproducible results in both in vitro apoptosis assays and in vivo xenograft models.

• Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) as...

  2026-03-27

  This thought-leadership article explores the evolving role of ibuprofen, not merely as a non-steroidal anti-inflammatory drug (NSAID), but as a mechanistically rich, strategically vital tool for translational researchers. We dissect its dual COX-1/COX-2 inhibition, anti-proliferative actions in colon carcinoma models, and emerging relevance in lipid metabolism and neuropathic pain—integrating advanced literature, protein interaction paradigms, and practical experimental guidance. Anchored by APExBIO’s Ibuprofen (SKU A8446), this article charts a visionary roadmap for leveraging ibuprofen in high-impact cancer, atherosclerosis, and inflammation research.

• (S)-(+)-Ibuprofen: Selective COX Inhibitor for Inflammati...

  2026-03-26

  (S)-(+)-Ibuprofen is the pharmacologically active ibuprofen enantiomer and a potent COX inhibitor essential for anti-inflammatory and pain mechanism studies. The compound displays high selectivity for COX-2, robust in vitro and in vivo parameters, and a well-characterized environmental profile, making it a cornerstone in nonsteroidal anti-inflammatory drug research.

• Ibuprofen (A8446): Dual COX Inhibitor and Anti-Proliferat...

  2026-03-26

  Ibuprofen, a non-steroidal anti-inflammatory drug, acts as a dual inhibitor of cyclooxygenase enzymes COX-1 and COX-2, demonstrating potent anti-inflammatory, anti-proliferative, and lipid-lowering effects in preclinical models. APExBIO’s Ibuprofen (A8446) enables reproducible research in cancer and cardiovascular disease by inducing apoptosis and modulating lipid metabolism pathways.

• Ibuprofen as a Molecular Probe: Advanced Mechanistic Insi...

  2026-03-25

  Explore ibuprofen’s role as a cyclooxygenase inhibitor and anti-proliferative agent in advanced cancer biology and lipid metabolism studies. This article delivers a unique systems-level perspective on ibuprofen’s mechanistic actions and research applications, offering depth beyond standard NSAID analyses.

16285 records 1/1086 page Next 12345 下5页 Last page